| Background: Chronic obstructive pulmonary disease (COPD) has been introduced as a
major public health problem. It has been suggested that disruption in function or some
adipokines and serum proteins' signaling could play crucial roles in lung diseases. This
study's purpose was to investigate the association between serum levels of S100A1, ZAG,
and adiponectin with FEV1 in COPD patients.
Methods: In this cross-sectional study, 90 clinically stable outpatient males with age
ranging from 40 to 70 years with COPD diagnosis – FEV1/FVC < 70% – were divided
into two groups: mild–moderate COPD patients; FEV1 ≥ 50 (n=52) VS severe and very
severe COPD patients; FEV1 < 50 (n=38). The serum levels of ZAG, S100A1, and
adiponectin were measured by the use of enzyme-linked immunosorbent assay.
Results: In the present study, lower FEV1 was significantly associated with increased risk of
cachexia (OR = 5.76, 95% CI: 2.28–14.54). The serum level of ZAG was significantly higher
in the mild–moderate COPD patients in comparison with the severe–very severe COPD
patients (p<0.035). However, the resting metabolic rate (RMR) level was significantly higher
in FEV1<50 group compared to FEV1≥50 group (p<0.024). Also, strong positive associations
between serum S100A1–ZAG, serum adiponectin–ZAG, and serum adiponectin–
S100A1 (β>0.800, p<0.001) were shown.
Conclusion: In the present study, we found that low FEV1 was associated with increased
risk of cachexia in COPD patients. Additionally, lower serum level of ZAG and higher RMR
were observed in patients with severe–very severe COPD as compared to mild–moderate
COPD. Therefore, it could be claimed that there is a mechanistic chain of causality between
FEV1, serum ZAG, RMR, and cachexia. |